Search 

Enterika Ltd is the first company to be supported by the QMIF. The company is developing weight-loss products aimed at tackling obesity, which is a significant risk factor for a range of chronic diseases. Enterika was successful with securing an Innovate UK grant to further develop the technology and has the support and interest from several investors.

Selcia is a global contract research provider of integrated drug discovery, medicinal chemistry and 14C radiolabeled compounds. Established in 2001, the company has two divisions: Selcia Drug Discovery - with medicinal chemistry,biology ADME and a unique peptidyl proyl isomerase (PPIase) inhibitor screening platform; and Selcia Radiolabeling - one of the world’s largest suppliers of custom 14C radiochemicals.

GlykoGen is developing a pipeline of anti-glycan antibodies to target ‘hard to treat’ cancers, including pancreatic cancer, using a novel selection process to prepare recombinant antibodies. GlykoGen’s vision is the delivery of more effective therapies for cancer, targeting cancer cells through their surface glycans. Glycans are of interest in the study of cancer because they play a key role in the function of cell surface glycoprotein, impacting the unique phenotypes of cancer cells.   Glycans are thought to be directly relevant cancer progression and therefore to treatment.  However the difficulties of producing antibodies to glycans has meant that their therapeutic potential in cancer remains to be exploited.

We are hVIVO plc (formerly Open Orphan plc) a rapidly growing specialist contract research organisation (CRO) and the world leader in testing infectious and respiratory disease vaccines and antivirals using human challenge clinical trials. We provide end-to-end early clinical development services for our broad and long-standing client base of global biopharma companies.

The Group's fast-growing services business includes a unique portfolio of 10+ human challenge models to test a broad range of infectious and respiratory disease products, world class challenge agent manufacturing, specialist drug development and clinical consultancy services via its Venn Life Sciences brand, and a lab offering via its hLAB brand, which includes virology, immunology biomarker and molecular testing. The Group offers additional clinical field trial services such as patient recruitment and clinical trial site services.

hVIVO runs challenge studies in London from its Whitechapel quarantine clinic, its state-of-the-art QMB clinic with its highly specialised on-site virology and immunology laboratory, and its clinic in Plumbers Row. To recruit volunteers / patients for its studies, the Company leverages its unique clinical trial recruitment capacity via its FluCamp volunteer screening facilities in London and Manchester.

Exhibiting at booth 50 with the UK delegation, IDEA is passionate about getting innovative products to patients with unmet needs and we particularly enjoy putting our full weight of innovative thinking and regulatory expertise behind innovative medicine.

Our aim is to provide pharmaceutical companies, and others involved in drug development, with the necessary tools to develop and screen novel anti-infective and anti-cancer compounds. In order to achieve this we will continue to expand the range of topoisomerase products and screening services we offer.